Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
Novo Nordisk’s another diabetes drug to disappear from the Russian market
Over the past three months, more than 9,000 packages have been released into civil circulation.
- By Newsdesk
- Russia
- Apr 14, 2023
Novo Nordisk has informed Roszdravnadzor that supply of the diabetes drug Rybelsus (semaglutide) will be discontinued in 2024. The drug will be available for purchase in pharmacies until the end of 2023.
Roszdravnadzor reminds patients that analogues, such as drugs containing the INN exenatide, dulaglutide, and liraglutide, are available on the Russian market. Approximately 94,000 packages of such drugs have been produced since the beginning of 2023.
Along with Rybelsus, another Novo Nordisk antidiabetic therapy, Ozempik, will also be phased out of the Russian market. Due to Ozempic's popularity as a weight-loss drug and reports of supply discontinuation, some pharmacy chains are selling the product at inflated prices.